BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 17, Issue 9
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report
Copyright: ©Author(s) 2026.
World J Clin Oncol. Sep 24, 2026; 17(9): 123454
Published online Sep 24, 2026. doi: 10.5306/wjco.123454
Table 1 Dynamic changes in liver function during treatment
Date
ALT (IU/L)
AST (IU/L)
Clinical context
November 19, 2021 (Baseline)106 ↑68 ↑Initial diagnosis, hepatic insufficiency
December 1, 202176 ↑63 ↑Pre-TAE, hepatoprotective therapy initiated
December 2, 2021--TAE procedure performed
December 5, 2021148 ↑73 ↑Post-TAE peak ALT
December 11, 20214679 ↑Gradual recovery
December 29, 2021130 ↑144 ↑Before cycle 2, transient elevation
January 3, 202289 ↑157 ↑Before cycle 2, AST peak
February 15, 20222934Normalized, chemotherapy resumed
ALT: Alanine aminotransferase; AST: Aspartate transaminase.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.